Regulation of lipid metabolism and gene expression by fenofibrate in hamsters

被引:54
作者
Guo, Q [1 ]
Wang, PR [1 ]
Milot, DP [1 ]
Ippolito, MC [1 ]
Hernandez, M [1 ]
Burton, CA [1 ]
Wright, SD [1 ]
Chao, YS [1 ]
机构
[1] Merck & Co Inc, Dept Atherosclerosis & Endocrinol, Rahway, NJ 07065 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2001年 / 1533卷 / 03期
关键词
hypolipidemia; gene regulation; hypolipidemic drug; fenofibrate; syrian hamster;
D O I
10.1016/S1388-1981(01)00156-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fenofibrate is a potent hypolipidemic agent that lowers plasma lipid levels and may thus decrease the incidence of atherosclerosis. Here we investigated the molecular mechanism of fenofibrate's hypolipidemic action by characterizing its in vivo effects on the expression of mRNAs and the activities of pivotal enzymes in cholesterol and triglyceride metabolism in the hamster. Treatment of hamsters with fenofibrate led to a dose-dependent reduction in serum cholesterol concentrations. Studies on the incorporation of [C-14]acetate and [C-14]mevalonate into cholesterol suggested that this effect occurs primarily through inhibition of cholesterol biosynthesis at steps prior to mevalonate. Fenofibrate decreased levels of hepatic enzyme activities and mRNAs for 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) synthase and HMG CoA reductase. A potential mechanism for transcriptional regulation of these enzymes is via SREBP-2 that we found to be suppressed 2-fold by fenofibrate. Fenofibrate also lowered circulatory triglyceride levels. In keeping with the effect, we observed strong suppression of fatty acid synthase, acetyl-CoA carboxylase and apolipoprotein C-III mRNA and stimulation of lipoprotein lipase and acyl-CoA oxidase mRNA in the liver of fenofibrate-treated hamsters. These observations suggest that the effect of fenofibrate on triglyceride metabolism is likely to be a result of both decreased fatty acid synthesis and increased lipoprotein lipase and acyl-CoA oxidase gene expression in the liver. Surprisingly, alterations in lipoprotein lipase, acyl-CoA oxidase, acetyl-CoA carboxylase, and apolipoprotein C-III could not be observed in hamster hepatocytes incubated with fenofibric acid in vitro. These observations raise the possibility that changes in these genes may be secondary to the metabolic alterations occurring in animals but not in cultured cells and thus that the effect of fenofibrate on these genes may be indirect. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:220 / 232
页数:13
相关论文
共 77 条
[1]   MEVINOLIN - A HIGHLY POTENT COMPETITIVE INHIBITOR OF HYDROXYMETHYLGLUTARYL-COENZYME-A REDUCTASE AND A CHOLESTEROL-LOWERING AGENT [J].
ALBERTS, AW ;
CHEN, J ;
KURON, G ;
HUNT, V ;
HUFF, J ;
HOFFMAN, C ;
ROTHROCK, J ;
LOPEZ, M ;
JOSHUA, H ;
HARRIS, E ;
PATCHETT, A ;
MONAGHAN, R ;
CURRIE, S ;
STAPLEY, E ;
ALBERSSCHONBERG, G ;
HENSENS, O ;
HIRSHFIELD, J ;
HOOGSTEEN, K ;
LIESCH, J ;
SPRINGER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (07) :3957-3961
[2]   CHOLESTEROL AND MORTALITY - 30 YEARS OF FOLLOW-UP FROM THE FRAMINGHAM-STUDY [J].
ANDERSON, KM ;
CASTELLI, WP ;
LEVY, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (16) :2176-2180
[3]   REGULATION OF GENE-EXPRESSION BY FATTY-ACIDS AND FIBRIC ACID-DERIVATIVES - AN INTEGRATIVE ROLE FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS - THE BELGIAN-ENDOCRINE-SOCIETY LECTURE 1992 [J].
AUWERX, J .
HORMONE RESEARCH, 1992, 38 (5-6) :269-277
[4]   A MULTICENTER COMPARISON OF THE EFFECTS OF SIMVASTATIN AND FENOFIBRATE THERAPY IN SEVERE PRIMARY HYPERCHOLESTEROLEMIA, WITH PARTICULAR EMPHASIS ON LIPOPROTEINS DEFINED BY THEIR APOLIPOPROTEIN COMPOSITION [J].
BARD, JM ;
PARRA, HJ ;
CAMARE, R ;
LUC, G ;
ZIEGLER, O ;
DACHET, C ;
BRUCKERT, E ;
DOUSTEBLAZY, P ;
DROUIN, P ;
JACOTOT, B ;
DEGENNES, JL ;
KELLER, U ;
FRUCHART, JC .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1992, 41 (05) :498-503
[5]   Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].
Berthou, L ;
Duverger, N ;
Emmanuel, F ;
Langouet, S ;
Auwerx, J ;
Guillouzo, A ;
Fruchart, JC ;
Rubin, E ;
Denefle, P ;
Staels, B ;
Branellec, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416
[6]   COMBINATION-DRUG THERAPY FOR DYSLIPIDEMIA [J].
BETTERIDGE, DJ .
CURRENT OPINION IN LIPIDOLOGY, 1993, 4 (01) :49-55
[7]   REVIEW OF EUROPEAN CLINICAL-EXPERIENCE WITH FENOFIBRATE [J].
BLANE, GF .
CARDIOLOGY, 1989, 76 :1-13
[8]   WHY PREFER THE GOLDEN SYRIAN-HAMSTER (MESOCRICETUS-AURATUS) TO THE WISTAR RAT IN EXPERIMENTAL STUDIES ON PLASMA-LIPOPROTEIN METABOLISM [J].
BRAVO, E ;
CANTAFORA, A ;
CALCABRINI, A ;
ORTU, G .
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B-BIOCHEMISTRY & MOLECULAR BIOLOGY, 1994, 107 (02) :347-355
[9]   The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor [J].
Brown, MS ;
Goldstein, JL .
CELL, 1997, 89 (03) :331-340
[10]   THE BIOCHEMICAL PHARMACOLOGY OF FENOFIBRATE [J].
CALDWELL, J .
CARDIOLOGY, 1989, 76 :33-44